Martín-Garcia A, López-Fernández T, Mitroi C, et al. - Researchers sought to ascertain the potential benefit of sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction (CTRCD). All patients treated with sacubitril/valsartan were assessed for this retrospective multicentre registry in six Spanish hospitals with cardio-oncology clinics. They identified 67 patients for inclusion (median age was 63 ± 14 years; 64% were female, 87% had at least one cardiovascular risk factor). Median time from anti-cancer therapy to CTRD was 41 [10; 141] months. The most frequent neoplasms were breast cancer (45%) and lymphoma (39%), metastatic disease was evident in 31%, and treatment to all patients was provided with combination antitumor therapy (70% with anthracyclines). Receipt of thoracic radiotherapy was reported in 39% of patients. They observed baseline median left ventricular ejection fraction of 33 [27; 37], and atrial fibrillation in 21%. Eighty-five percent were receiving beta-blocker therapy and 76% were on mineralocorticoid receptor antagonists; 90% of the patients were symptomatic New York Heart Association functional class ≥ II. In 8% of patients, attainment of maximal sacubitril/valsartan titration dose was observed (50 mg BID: 60%; 100 mg BID: 32%). As per observations, patients with CTRCD well-tolerated sacubitril/valsartan and showed improvement in echocardiographic functional and structural parameters, N-terminal pro-B-type natriuretic peptide levels, and symptomatic status in correlation to receiving sacubitril/valsartan.